Sarah N. Flier

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay”.

Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay

Journal of Clinical Medicine(2020)10.3390/jcm9092840

N/A

0DataRank · unranked

2 citations

Valerio J. Thomas, Andrea Banty, William T. Clarke, Katharine A. Germansky, Sarah N. Flier +4 more

Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor

Clinical Gastroenterology and Hepatology(2021)10.1016/j.cgh.2021.01.006

N/A

0DataRank · unranked

29 citations

María T. Abreu, Sarah N. Flier, Konstantinos Papamichael, Florian Rieder, Mark S. Silverberg +6 more

Patient Perspective on Safety of Elective Gastrointestinal Endoscopy During the COVID-19 Pandemic

Techniques and Innovations in Gastrointestinal Endoscopy(2021)10.1016/j.tige.2021.05.001

N/A

0DataRank · unranked

4 citations

Mohammed El-Dallal, Mohammad Bilal, Sarah N. Flier, Sunil G. Sheth, Sarah Ballou +5 more